



**HAL**  
open science

## Differential Sensitivity To Adrenergic Stimulation Underlies The Sexual Dimorphism In The Development Of Diabetes Caused By Irs-2 Deficiency

Maria Jose Garcia-Barrado, Maria Carmen Iglesias-Osma, Veronica Moreno-Viedma, Maria Francisca Pastor Mansilla, Silvia Sanz Gonzalez, Jose Carretero, Julio Moratinos, Deborah J. Burks

### ► To cite this version:

Maria Jose Garcia-Barrado, Maria Carmen Iglesias-Osma, Veronica Moreno-Viedma, Maria Francisca Pastor Mansilla, Silvia Sanz Gonzalez, et al.. Differential Sensitivity To Adrenergic Stimulation Underlies The Sexual Dimorphism In The Development Of Diabetes Caused By Irs-2 Deficiency. *Biochemical Pharmacology*, 2010, 81 (2), pp.279. 10.1016/j.bcp.2010.10.008 . hal-00649886

**HAL Id: hal-00649886**

**<https://hal.science/hal-00649886v1>**

Submitted on 9 Dec 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Title: Differential Sensitivity To Adrenergic Stimulation Underlies The Sexual Dimorphism In The Development Of Diabetes Caused By Irs-2 Deficiency

Authors: Maria Jose Garcia-Barrado, Maria Carmen Iglesias-Osma, Veronica Moreno-Viedma, Maria Francisca Pastor Mansilla, Silvia Sanz Gonzalez, Jose Carretero, Julio Moratinos, Deborah J. Burks

PII: S0006-2952(10)00764-1  
DOI: doi:10.1016/j.bcp.2010.10.008  
Reference: BCP 10740

To appear in: *BCP*

Received date: 30-6-2010  
Revised date: 7-10-2010  
Accepted date: 11-10-2010

Please cite this article as: Garcia-Barrado MJ, Iglesias-Osma MC, Moreno-Viedma V, Mansilla MFP, Gonzalez SS, Carretero J, Moratinos J, Burks DJ, Differential Sensitivity To Adrenergic Stimulation Underlies The Sexual Dimorphism In The Development Of Diabetes Caused By Irs-2 Deficiency, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.10.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**DIFFERENTIAL SENSITIVITY TO ADRENERGIC STIMULATION  
UNDERLIES THE SEXUAL DIMORPHISM IN THE DEVELOPMENT  
OF DIABETES CAUSED BY IRS-2 DEFICIENCY**

**Abbreviated Title: Female *Irs2*<sup>-/-</sup> Mice Display Catecholamine Resistance.**

Maria Jose Garcia-Barrado<sup>1</sup>, Maria Carmen Iglesias-Osma<sup>1</sup>, Veronica Moreno-Viedma<sup>4</sup>,  
Maria Francisca Pastor Mansilla<sup>2</sup>, Silvia Sanz Gonzalez<sup>4</sup>, Jose Carretero<sup>3</sup>, Julio Moratinos<sup>1</sup>,  
Deborah J. Burks<sup>4</sup>

<sup>1</sup> Department of Physiology and Pharmacology, Faculty of Medicine, University of  
Salamanca, Salamanca, Spain

<sup>2</sup> University of Valladolid, Valladolid, Spain

<sup>3</sup> Department of Anatomy, Faculty of Medicine, University of Salamanca, Salamanca, Spain

<sup>4</sup> Regenerative Medicine Program, CIBER de Diabetes y Enfermedades Metabólicas  
(CIBERDEM), Centro de Investigación Príncipe Felipe, Valencia, Spain

**Key Words: Insulin, Diabetes, Adrenergic Receptors, Lipolysis, cAMP**

**Address Correspondence to:**  
**Deborah Burks, Ph.D.**  
**Centro de Investigacion Principe Felipe**  
**Avenida del Autopista del Saler, 16**  
**46013 Valencia, Spain**  
**TEL: (34) 963289680**  
**FAX: (34) 963289701**  
**Email: [dburks@cipf.es](mailto:dburks@cipf.es)**

**Disclosure Statement: The authors have no conflicts of interest to disclose.**

**ABSTRACT**

1 The diabetic phenotype caused by the deletion of insulin receptor substrate-2 (Irs-2) in  
2  
3 mice displays a sexual dimorphism. Whereas the majority of male Irs-2<sup>-/-</sup> mice are overtly  
4  
5 diabetic by 12 weeks of age, female Irs-2<sup>-/-</sup> animals develop mild obesity and progress less  
6  
7 rapidly to diabetes. Here we investigated  $\beta$ -cell function and lipolysis as potential  
8  
9 explanations for the gender-related differences in this model. Glucose-stimulated insulin  
10  
11 secretion was enhanced in islets from male null mice as compared to male WT whereas this  
12  
13 response in female Irs-2<sup>-/-</sup> islets was identical to that of female controls. The ability of  $\alpha_2$ -  
14  
15 adrenoceptor ( $\alpha_2$ -AR) agonists to inhibit insulin secretion was attenuated in male Irs2 null  
16  
17 mice. Consistent with this, the expression of the  $\alpha_{2A}$ -AR was reduced in male Irs-2<sup>-/-</sup> islets.  
18  
19 The response of male Irs-2<sup>-/-</sup> islets to forskolin was enhanced, owing to increased production  
20  
21 of cAMP. Basal lipolysis was increased in male Irs-2<sup>-/-</sup> but decreased in female Irs-2<sup>-/-</sup> mice,  
22  
23 concordant with the observation that adipose tissue is sparse in males whereas female Irs2  
24  
25 null mice are mildly obese. Adipocytes from both male and female Irs-2<sup>-/-</sup> were resistant to the  
26  
27 anti-lipolytic effects of insulin but female Irs-2<sup>-/-</sup> fat cells were additionally resistant to the  
28  
29 catabolic effects of beta-adrenergic agonists. This catecholamine resistance was associated  
30  
31 with impaired generation of cAMP. Consequently, targets of cAMP-dependent protein kinase  
32  
33 (PKA) which mediate lipolysis were not phosphorylated in adipose tissue of female Irs-2<sup>-/-</sup>  
34  
35 mice. Our findings suggest that IRS-2 deficiency in mice alters the expression and/or  
36  
37 sensitivity of components of adrenergic signaling.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 1. INTRODUCTION

1  
2  
3  
4 The presence of a sexual dimorphism is observed in almost all mouse models of  
5 diabetes, including those generated by altering insulin signaling, with males displaying a  
6 predominance of the diabetic phenotype [1-4]. However, with the non-obese diabetes (NOD)  
7 mouse model of type 1 diabetes, there is a strong tendency for females to develop diabetes,  
8 even though both genders present lymphocytic infiltration of the islets [5, 6]. The specific  
9 factors which mediate sexual dimorphisms remain largely unexplained in these experimental  
10 models of diabetes. Thus, the molecular mechanisms underlying the gender-specific  
11 differences which modulate the development and progression of diabetes may provide  
12 important clues for the design of anti-diabetic drugs or therapies in human patients.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24

25 Various lines of evidence suggest that catecholamines and adrenergic receptors are  
26 involved in the etiology and pathogenesis of type 2 diabetes mellitus [7, 8], which is  
27 characterized by an insufficient secretion of insulin to compensate for resistance to insulin  
28 action in peripheral tissues [9]. Indeed, the plasma concentrations of catecholamines are  
29 higher in diabetic than in healthy subjects [10, 11] and glucose intolerance is frequently  
30 observed in patients with endocrine disorders such as pheochromocytoma ([12, 13]. The anti-  
31 secretagogue effect of catecholamines is mediated primarily by the stimulation of alpha 2-  
32 adrenoceptors ( $\alpha_2$ -AR) in pancreatic beta cells, suggesting that increased sympathetic  
33 innervation or a reinforced  $\alpha_2$ -adrenergic response in pancreatic islets may account for the  
34 impaired secretory response to glucose observed in certain forms of type 2 diabetes [14, 15].  
35 Adrenaline and other  $\alpha_2$ -adrenoceptor agonists inhibit insulin secretion by a number of  
36 mechanisms coupled to the Gi/Go signaling system, including inhibition of adenylate cyclase  
37 (AC) and cAMP production [16], activation of  $K^+$  channels [17, 18], and inhibition of L-type  
38 voltage-dependent  $CA^{+2}$  channels [19]. Generation of mice deficient in  $\alpha_2$ -AR subtypes has  
39 demonstrated that insulin secretion is modulated principally by the  $\alpha_{2A}$  AR; the absence of  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 inhibitory pancreatic beta-cell  $\alpha_{2A}$ -AR function causes hyperinsulinaemia, reduced blood  
2 glucose levels and improved glucose tolerance in knockout mice [20]. Conversely,  
3  
4 overexpression of  $\alpha_{2A}$ -AR specifically in beta cells causes hyperglycemia in response to  $\alpha_{2}$ -  
5  
6 AR agonists due to reduced insulin secretion [21]. A recent study has demonstrated that a  
7  
8 single-nucleotide polymorphism in the human *ADRA2A* gene is associated with  
9  
10 overexpression of  $\alpha_{2A}$ -AR, reduced insulin secretion, and increased risk for type 2 diabetes  
11  
12 [22]. Consistent with these findings, a genome-wide association (GWA) project has recently  
13  
14 linked the *ADRA2A* locus with beta-cell dysfunction in humans with Type 2 diabetes [23].  
15  
16  
17

18  
19 Given that obesity is closely associated with the development of diabetes, the effects  
20  
21 of catecholamines on the metabolic parameters of white and brown adipose tissue represent  
22  
23 another target for intervention in this disease ([24]. The three  $\beta$ -adrenergic receptor ( $\beta$ -AR)  
24  
25 subtypes ( $\beta$ -AR1,  $\beta$ -AR2, and  $\beta$ -AR3) are coupled to  $G_{\alpha s}$  for increasing intracellular cAMP  
26  
27 levels [25]. In white adipose tissue, lipolysis is regulated by activation of adenylyl cyclase and  
28  
29 cAMP-dependent protein kinase (PKA) which stimulates lipase, the enzyme that catalyzes the  
30  
31 breakdown of triacylglycerol into glycerol and free fatty acids (FFA) [26]. By contrast,  
32  
33 activation of  $\alpha_{2}$  - adrenoceptors inhibits lipolysis [27]. In most models of obesity, the  $\beta$ -AR  
34  
35 system is dysfunctional [28] leading to impairments of lipolysis and thermogenesis. However,  
36  
37 whereas activation of the  $\beta$ -AR subtypes can stimulate lipolysis, the involvement of each  
38  
39 subtype varies according to fat location, species, gender, age, and degree of obesity [29].  
40  
41 Interestingly, selective agonists for the  $\beta$ -AR3, the subtype expressed predominantly in  
42  
43 adipocytes [30], prevent or reverse obesity and accompanying insulin resistance in animal  
44  
45 models. Whether these agonists represent a viable therapeutic option for human obesity is  
46  
47 much debated. Nevertheless, the physiological changes in adrenoceptor function associated  
48  
49 with obesity in rodent models have yielded beneficial insights into  $\beta$ -AR signaling and  
50  
51 adipocyte physiology.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Members of the insulin receptor substrate (IRS) protein family mediate the physiological effects of insulin and IGF-I [31]. Deletion of IRS-2 produces diabetes in mice owing to peripheral insulin resistance and a reduction in pancreatic  $\beta$ -cell mass [32]. However, this diabetic phenotype displays a sexual dimorphism; male *Irs-2*<sup>-/-</sup> mice often die of diabetic complications by 12 weeks of age but female *Irs-2*<sup>-/-</sup> develop a milder form of diabetes and many live up to 6 months [33, 34]. Additionally, female *Irs-2* deficient mice display hyperleptinemia and develop moderate obesity [35, 36], in contrast to male *Irs-2*<sup>-/-</sup> which are often leaner than control mice. In the present study, we used a pharmacological approach to 1) characterize in greater detail the sexual dimorphism of the *Irs-2*<sup>-/-</sup> model with respect to beta cell function and lipolysis and 2) to explore the contributions of adrenergic signaling to the diabetic phenotype of *Irs-2* deficient animals.

## 2. MATERIAL AND METHODS

1  
2  
3  
4 **2.1. Animal Experimentation.** The generation and genotyping of mice deficient for *Irs-2*<sup>-/-</sup>  
5  
6 have been described previously [3]. The mice used in the present study were maintained on a  
7  
8 C57Bl6 background and were allowed free access to food (irradiated chow, Harlan 20/14) and  
9  
10 water during controlled light-dark cycles of 12 hours. All mice were studied at 8-10 weeks of  
11  
12 age and any which were overtly diabetic (>220 fed glucose mg/dl or 120 fasted glucose  
13  
14 mg/dl) were excluded in order to examine the consequences of *Irs-2*<sup>-/-</sup> deficiency under  
15  
16 conditions which minimize the complications of diabetic metabolism. For routine  
17  
18 measurements of fasting glucose and insulin, mice were fasted for 16 hours and a small  
19  
20 quantity of tail blood was extracted for immediate analysis by a glucometer (Bayer Elite  
21  
22 model, Bayer Healthcare, Barcelona, Spain). Circulating insulin was measured by a mouse  
23  
24 ultra-sensitive ELISA (Mercodia, Uppsala, Sweden, <http://www.mercodia.se>). When fed  
25  
26 values for insulin and glucose were assessed by these same methods, tail blood was collected  
27  
28 consistently between 10 and 11 AM. All experimental procedures were approved by the  
29  
30 institutional committee for animal experimentation.  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 **2.2. Adipocyte isolation and lipolysis assay.** The details of this experimental procedure have  
41  
42 been described previously [37]. Briefly, intra-abdominal white adipose tissue (WAT) of peri-  
43  
44 renal and epididymal origin was removed from fed animals. Adipose tissue was digested for  
45  
46 35 to 45 min at 37 °C under shaking with 1.5 mg/ml collagenase A (Roche Diagnostics,  
47  
48 Mannheim, Germany) in Krebs-Ringer containing 15 mM sodium bicarbonate, 6 mM  
49  
50 glucose, 10 mM HEPES, and bovine serum albumin (35 mg/ ml) adjusted to pH 7.4 (KRBA  
51  
52 buffer). Isolated fat cells were filtered and washed three times in KRBA buffer to eliminate  
53  
54 collagenase. The packed cells were diluted in around 10-fold their volume of KRBA, and  
55  
56 500 µl of cell suspension was distributed into plastic incubation vials. Therefore, after 90-min  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 incubation under gentle shaking at 37 °C with the indicated final concentration of tested  
2 drugs, the glycerol released into the medium was assayed and lipolytic activity was expressed  
3 as  $\mu$ moles of glycerol released/100 mg of cellular lipid/90 min. Changes in glycerol release  
4 are expressed as percentages of mean control. A one-way analysis of variance (ANOVA) and  
5 the Newman–Keuls test were used for statistical analysis. Results were considered significant  
6 if  $P < 0.05$ .  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16

17 **2.3. Islet isolation and measurement of insulin secretion/content.** Islets were isolated by  
18 collagenase digestion (Immunogenetics, Madrid, Spain) of the pancreas of fed female and male  
19 WT and IRS-2<sup>-/-</sup> mice, followed by manual selection using a dissecting microscope [38]. They  
20 were free of visible exocrine contamination. The medium used for islet isolation was a  
21 bicarbonate-buffered solution (HCO<sub>3</sub> medium) containing 120 mM NaCl, 4.8 mM KCl, 2.5  
22 mM CaCl<sub>2</sub>, 1.2 mM MgCl<sub>2</sub>, 5 mM HEPES and 24 mM NaHCO<sub>3</sub>. It was equilibrated with O<sub>2</sub>-  
23 CO<sub>2</sub> (94:6) to maintain a pH of 7.4 and was supplemented with 1 mg ml<sup>-1</sup> BSA and 10 mM  
24 glucose. After isolation, the islets were pre-incubated for 60 min in HCOS medium containing  
25 15 mM glucose before being distributed into batches of three. Each batch of islets was then  
26 incubated for 60 min in 1 ml at 37°C of medium containing glucose and test substances. A  
27 portion of the medium was withdrawn at the end of the incubation to measure the insulin  
28 concentration. Additionally, the islets were recovered following the incubation and total  
29 insulin content was determined after extraction in acid-ethanol [39]. Insulin was measured by  
30 a double-antibody RIA (Schering Laboratories, Madrid, Spain). Calculations and statistics  
31 were performed with the Instat software  
32 (GraphPad, San Diego, CA, USA). Results are provided as mean  $\pm$  S.E.M.  
33 Statistical significance was assessed by the Student's t-test or the  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

one-way analysis of variance (ANOVA) corrected by the Newman–Keuls test. Results were considered significant if  $P < 0.05$ .

**2.4. Immunohistochemistry and quantification of beta cell area.** Pancreata were removed at the time of sacrifice and fixed for 16 hours in Bouin's solution (Sigma, Steinheim, Germany, <http://www.sigmaaldrich.com>). Subsequently, pancreatic tissue was embedded in paraffin and sections of 5  $\mu$ m were prepared. Following re-hydration and permeabilization with 1% Triton X-100, sections were incubated with anti-insulin (Sigma, <http://www.sigmaaldrich.com>) and anti-glucagon (Sigma, <http://www.sigmaaldrich.com>) antibodies overnight at 4°C. Detection was performed with rhodamine and fluorescein conjugated secondary antibodies (Jackson ImmunoResearch, USA, [www.jacksonimmuno.com](http://www.jacksonimmuno.com)). For quantification of  $\beta$ -cell area, sections were viewed using a Zeiss Axiovert S100 TV microscope at a magnification of 10x. The islet cross-sectional area and total pancreatic area were measured using Openlab Image analysis software (Improvision Imaging). At least 3 sections, separated by 200  $\mu$ m were measured per animal. For quantification of the number of islets per area, only islets with more than 5 cells were scored.

**2.5. Western Blotting.** Abdominal fat depots were collected and frozen immediately in liquid nitrogen. Tissue was lysed in RIPA buffer (NaCl 150mM, Tris 50mM, EDTA 1mM, EGTA 1mM, SDS 0.1%, Sodium deoxycholate 0.5%, NP-40 1%,  $\text{Na}_3\text{VO}_4$  1mM, NaF 1mM) by polytron and homogenates were clarified by centrifugation at 12,000  $\times$  g for 10 min. Protein determination was by the Biorad assay. 50  $\mu$ g of total protein was separated by SDS-PAGE. Gels were transferred to Immun-Blot<sup>TM</sup> PVDF Membrane (Bio-Rad Laboratories, Hercules CA, [www.bio-rad.com](http://www.bio-rad.com)) and incubated with one of the following antibodies: rabbit anti-phospho PKA substrate (Cell Signaling, <http://www.cellsignal.com>), anti-perilipin A/B

(Sigma, <http://www.sigmaaldrich.com>), rabbit anti-alpha2A adrenergic receptor (Acris Antibodies, Hiddenhausen, Germany, [www.acris-antibodies.com](http://www.acris-antibodies.com)), or anti-hormone sensitive lipase (Santa Cruz, <http://www.scbt.com/>), or rabbit anti-beta tubulin (Sigma, <http://www.sigmaaldrich.com>). Westerns were developed by ECL (Pierce, Thermo Scientific, Rockford IL, <http://www.piercenet.com/>).

**2.6. Measurement of Intracellular cAMP Content.** Islets were isolated as described above in batches of 100 size-matched islets. Subsequently, the medium was changed to adjust glucose concentrations to 3mM or 15mM, with or without forskolin, in KRBH containing 1mM isobutylmethylxanthine (IBMX) which prevents cAMP degradation by inhibiting cyclic nucleotide phosphodiesterases. Following a 30 min incubation at 37°C, islets were collected by centrifugation and the pellet was frozen immediately in liquid N<sub>2</sub>. Adipocytes were isolated and incubated with pharmacological agents as described above. Intracellular cAMP levels were assessed using the AlphaScreen cAMP kit (Perkin-Elmer, Massachusetts, USA <http://las.perkinelmer.com>). Statistical significance was evaluated by the Student's t-test. Results are expressed as mean  $\pm$  S.E.M.

### 3. RESULTS

#### **3.1. Metabolic differences between male and female IRS2-deficient mice cannot be explained by beta cell number or insulin content.**

To explore the physiological basis of the sexual dimorphism in the *Irs2* knockout model, we first measured fed blood glucose and insulin levels in mice of 8-10 weeks of age. Fed plasma glucose values in both male and female *Irs2*<sup>-/-</sup> mice were higher than in their WT controls (Fig. 1A), although the differences were less pronounced in female mice. Mice which were overtly diabetic (>220 fed glucose mg/dl or 120 fasted glucose mg/dl) were excluded from study in order to examine the contributions of *Irs2*<sup>-/-</sup> deficiency under conditions which

1 minimize the complications of diabetic metabolism. Both male and female *Irs-2<sup>-/-</sup>* displayed  
2 higher fed insulin values in comparison to their WT controls, although this was statistically  
3 significant only in males (Fig. 1B). Consistent with previous reports, the female *Irs2<sup>-/-</sup>* mice in  
4 our study weighed more than their WT controls (*Irs2<sup>-/-</sup>*: 19.3 grams  $\pm$  2.40, WT: 15.9 g  $\pm$  2.23;  
5  $p < 0.05$ , n=10 mice of each genotype) whereas no differences were observed between the  
6 body weights of male transgenic and control mice (*Irs2<sup>-/-</sup>*: 20.6 grams  $\pm$  2.19, WT: 20.3 g  $\pm$   
7 2.05; n=10 mice of each genotype). To determine whether the metabolic differences between  
8 male and female IRS2-deficient mice could be explained by differences in the beta cell  
9 population, histological analysis was performed. Beta cell mass was reduced in both males  
10 and females, although to a slightly lesser extent in females (male *Irs-2<sup>-/-</sup>*: 40.2% vs. female *Irs-*  
11 *2<sup>-/-</sup>*: 28.5%) (Fig. 1C). When total pancreas insulin content was evaluated (Figure 1D), it was  
12 reduced similarly in male and female *Irs-2<sup>-/-</sup>* mice (males: WT 1,719  $\pm$  145 vs. *Irs-2<sup>-/-</sup>*: 1.287  
13  $\pm$  44 mIU/islet; females: WT 1,202  $\pm$  105 vs. *Irs-2<sup>-/-</sup>* 928  $\pm$  76 mIU/islet). The integrity of the  
14 insulin secretory response to glucose was evaluated by measuring glucose-stimulated insulin  
15 release from isolated islets. In response to various concentrations of glucose, islets from *Irs-2<sup>-/-</sup>*  
16 *-* males secreted more insulin than WT controls whereas the response of female *Irs-2<sup>-/-</sup>* was  
17 identical to WT control females (Fig. 1E, F). Thus, the rapid progression of diabetes in males  
18 *Irs2* null mice could not be explained by gender differences in beta cell area and insulin  
19 content but was associated with defective insulin secretion.

### 20 **3.2. Secretion of insulin by male *Irs-2<sup>-/-</sup>* islets displays altered sensitivity to adrenergic** 21 **agonists and forskolin**

22 Since it is well established that the sympathetic nervous system can modulate insulin  
23 secretion, we tested the effect of various types of pharmacological agonists on insulin release  
24 under conditions where glucose was maintained at 15 mM. The muscarinic agonist carbachol  
25 increased insulin secretion equivalently in islets from all genotypes (Fig. 2A). Brimonidine  
26

1 (UK 14,304), an agonist for  $\alpha_2$  adrenoceptors, at a dose of 1  $\mu$ M reduced insulin secretion as  
2 expected in control islets (figure 2A). However, inhibition of insulin secretion by this  $\alpha_2$   
3 agonist in male *Irs2*<sup>-/-</sup> was significantly less efficient than its effect on WT islets. We reasoned  
4 that this decreased sensitivity to brimonidine might reflect down-regulation of  $\alpha_2$ -AR or  
5 modifications of cAMP signalling components at the post-receptor level. To test these  
6 possibilities, we performed Western blot analysis and, interestingly, observed that expression  
7 of  $\alpha_{2A}$ -AR was reduced in islets of male *Irs-2*<sup>-/-</sup> mice (Figure 2B).  
8  
9

10  
11  
12  
13  
14  
15  
16  
17 Based on these observations, we tested the response of *Irs-2*<sup>-/-</sup> islets to forskolin, a  
18 direct activator of adenylate cyclase which is known to promote insulin secretion by  
19 increasing intracellular cAMP. The response of male *Irs-2*<sup>-/-</sup> islets to forskolin was enhanced  
20 in comparison to WT controls, whereas female *Irs-2*<sup>-/-</sup> islets displayed a slight decrease in the  
21 response to this cAMP agonist (Figure 2C). To further explore this altered response, we  
22 measured cAMP production in islets stimulated with either glucose or forskolin. The  
23 generation of cAMP in islets of male *Irs-2*<sup>-/-</sup> displayed enhanced sensitivity to both glucose  
24 and forskolin (Figure 2D), consistent with the insulin secretion results. In contrast, islets of  
25 female *IRS2*-deficient mice produced less cAMP in response to forskolin than female  
26 controls. These results suggest that the increased sensitivity of cAMP-generation in islets of  
27 male *Irs2*<sup>-/-</sup> males, combined with reduced expression of  $\alpha_{2A}$ -AR, contributes to the  
28 dysregulated insulin secretion and hyperinsulinemia observed in these animals.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

### 49 **3.3. Basal and Insulin-inhibited Lipolysis in Males vs. Females**

50  
51 As mentioned previously, female *Irs-2*<sup>-/-</sup> develop moderate obesity whereas body  
52 weight of males is comparable to their WT controls, at least during the pre-diabetic phase.  
53 Although *Irs2*<sup>-/-</sup> is known to have an important role in hypothalamic regulation of appetite and  
54 obesity [36, 40], we considered the possibility that adipose metabolism might also contribute  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

to differences between male and female *Irs-2<sup>-/-</sup>*. Therefore, we measured glycerol release in adipocytes isolated from male and female mice of both genotypes. Basal lipolysis in male *Irs-2<sup>-/-</sup>* was increased by 21% whereas it was reduced in females *Irs-2<sup>-/-</sup>* by 19%, in comparison to their respective WT controls (Figure 3A). When we tested the effects of insulin on lipolysis in isolated adipocytes, this hormone suppressed glycerol release effectively at both concentrations ( $10^{-8}$  and  $10^{-7}$  M) in WT animals (Figure 3B, C). In contrast, lipolysis was not inhibited significantly by insulin in male (Figure 3B) or female *Irs-2<sup>-/-</sup>* adipocytes (Figure 3C), suggesting that these animals are resistant to insulin action. Previous studies have demonstrated that IRS2-deficiency causes peripheral insulin resistance, particularly in liver [41].

#### **3.4. Adipocytes of female *Irs-2<sup>-/-</sup>* mice display resistance to $\beta$ -adrenergic-mediated lipolysis**

One of the major counter-regulatory mechanisms for controlling lipolysis is the adrenergic system. Catecholamines modulate lipolysis through lipolytic  $\beta$ -adrenoceptor and anti-lipolytic  $\alpha_2$ -adrenoceptor [24]. Given the altered basal lipolysis in male and female *Irs-2<sup>-/-</sup>*, we examined the effects of adrenergic stimulation on isolated adipocytes. Isoproterenol, a classic  $\beta$ -agonist, increased lipolysis in adipocytes from male WT and *Irs-2<sup>-/-</sup>* in a dose-dependent manner (Figure 4A). In sharp contrast, adipocytes isolated from female *Irs-2<sup>-/-</sup>* displayed a blunted response to isoproterenol, particularly at high concentrations ( $10^{-7}$  and  $10^{-6}$  M) of this agonist. (Figure 4B). This defective response to  $\beta$ -adrenergic agonists in female *Irs-2<sup>-/-</sup>* fat cells may reflect an inability to elevate intracellular cAMP, owing either to impaired cAMP generation or an increase to its degradation. We next tested the effects of the  $\alpha_2$ -adrenergic agonist brimonidine on isoproterenol-stimulated lipolysis which would be expected to inhibit given that  $\alpha_{2A}$ -AR decreases adenylate cyclase activity. At the highest dose

1 (10<sup>-6</sup> M) isoproterenol, brimonidine attenuated significantly glycerol release in male and  
2 female WT adipocytes (Figure 4C and D). However, in male *Irs-2<sup>-/-</sup>* fat cells, brimonidine had  
3  
4 no effect on isoproterenol-induced lipolysis, consistent with the reduced sensitivity to  
5  
6 brimonidine observed in islets of male null mice. The inhibitory effects of brimonidine on  
7  
8 lipolysis were also not significant in female *Irs-2<sup>-/-</sup>* adipocytes but this is most likely explained  
9  
10 by the apparent resistance of these cells to isoproterenol.  
11  
12  
13  
14  
15  
16

### 17 **3.5. Female *Irs-2<sup>-/-</sup>* adipocytes are less sensitive to forskolin**

18  
19 To investigate whether the resistance to  $\beta$ -adrenergic agonists in female *Irs-2<sup>-/-</sup>*  
20  
21 adipocytes reflects alterations at the receptor or post-receptor level, the effects of forskolin on  
22  
23 lipolysis were tested. In male *Irs-2<sup>-/-</sup>* fat cells, forskolin (10<sup>-5</sup> M) increased basal lipolysis to a  
24  
25 greater extent than in WT (40% of control,  $p < 0.001$ , Figure 5A). However, forskolin was less  
26  
27 effective at stimulating lipolysis in adipocytes of female transgenics as compared to female  
28  
29 WT controls (20% less glycerol was released when compared with WT,  $p < 0.001$ , figure 5B).  
30  
31  
32  
33

34 Given the dampened response to both  $\beta$ -adrenergic agonists and forskolin in female  
35  
36 *Irs-2<sup>-/-</sup>* adipocytes, we next evaluated cAMP generation in response to these agents. Consistent  
37  
38 with the lipolysis data, generation of cAMP in adipocytes of male *Irs-2<sup>-/-</sup>* mice displayed  
39  
40 increased sensitivity to forskolin. In contrast, the ability of isoproterenol as well as forskolin  
41  
42 to promote cAMP accumulation was attenuated in adipocytes of female *Irs-2<sup>-/-</sup>* as compared  
43  
44 with female controls. Thus, these results reveal a potential explanation for the failure of  
45  
46 forskolin and isoproterenol to stimulate lipolysis in adipocytes derived from female *IRS2*-  
47  
48 deficient mice.  
49  
50  
51  
52  
53  
54  
55

### 56 **3.6. cAMP signalling and expression of hormone sensitive lipase are reduced in adipose** 57 58 **tissue of female *Irs-2<sup>-/-</sup>* mice**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Perilipin A (Plin) is a major lipid droplet protein that regulates basal and PKA-stimulated lipolysis [42, 43]. Plin is required for the translocation of hormone-sensitive lipase (HSL) from the cytosol to lipid droplets upon stimulation [44]. When catecholamines bind to their receptors and initiate signals that increase cAMP, PKA phosphorylates Plin A which then promotes the translocation of HSL to facilitate maximal lipolysis. Thus, to determine whether the reduced ability to elevate cAMP agents in female *Irs-2*<sup>-/-</sup> adipocytes has consequences for downstream targets of the lipolytic pathway, we examined the phosphorylation of Plin A/B in adipose tissue lysates by Western blotting with an antibody specific for substrates of PKA. Although total expression levels were similar between *Irs-2* males and WT males as well as between *Irs-2* females and WT females, basal PKA-mediated phosphorylation of Plin A/B was notably reduced in the adipose tissue of *Irs-2* deficient females (Fig. 6A). These results suggest that reduced sensitivity to cAMP-elevating agents impairs the PKA pathway in adipose tissue of female *Irs2* null mice. Additionally, the expression of HSL was notably reduced in adipocytes of female *Irs-2*<sup>-/-</sup> mice (Fig. 6B). Collectively, these alterations may explain the reduced lipolysis and increased body weight of female *Irs2*-deficient mice.

#### 4. DISCUSSION

The development of diabetes in *Irs-2*<sup>-/-</sup> null mice has been well-characterized and is attributed to beta cell insufficiency paired with severe insulin resistance [32]. However, the sexual dimorphism associated with this diabetic phenotype is poorly understood. In our study, circulating insulin levels were not significantly different between WT and *Irs2*<sup>-/-</sup> females. However, male *Irs-2*<sup>-/-</sup> animals were hyperinsulinemic when compared with their WT controls. Consistent with this, glucose-stimulated insulin secretion was enhanced in islets from male *Irs-2*<sup>-/-</sup> whereas no difference was observed between female WT and *Irs-2*<sup>-/-</sup>



1 animals. The metabolic differences between male and female IRS2-deficient mice could not  
2 be explained on the basis of differential defects in the  $\beta$ -cell population and/or insulin content.  
3  
4  $\beta$ -cell mass was reduced in *Irs2* null mice of both genders, though to a slightly lesser extent in  
5  
6 females and insulin content was diminished to a similar extent in both male and female  
7  
8 transgenic mice.  
9

10  
11 This compensatory hyperinsulinemia could derive from an adaptive response of the  
12  
13 autonomic nervous system to the pathology of pre-diabetes since differences were observed  
14  
15 when we analysed the inhibitory effect of the adrenergic agents on insulin secretion.  
16  
17 Brimonidine, an  $\alpha_2$ -AR agonist, inhibited insulin secretion less efficiently in male *Irs-2<sup>-/-</sup>* mice  
18  
19 than in their WT controls. Additionally, the expression of this  $\alpha_{2A}$ -AR was down-regulated in  
20  
21 male but not in female IRS2-deficient islets, consistent with the reduced response to the  
22  
23 inhibitory effects of  $\alpha_2$ -AR on insulin release. Since  $\alpha_{2A}$ -AR appears to be the main receptor  
24  
25 in beta cells and mediates the inhibition of adenylate cyclase, reduced expression of this  
26  
27 receptor would be expected to favor increased intracellular levels of cAMP [45, 46].  
28  
29 Therefore, dysregulation of cAMP could explain the enhanced insulin secretory response to  
30  
31 both glucose and forskolin observed in islets of male *Irs-2<sup>-/-</sup>* mice. Indeed, the cAMP-  
32  
33 dependent guanine nucleotide exchange factor EPAC potentiates exocytosis by interacting  
34  
35 with  $K^+$ ATP and  $Ca^{+2}$  voltage channels and by promoting granule fusion events. [47].  
36  
37 Chronic, elevated insulin levels have been reported in  $\alpha_2$ -AR<sup>-/-</sup> mice and animals deprived of  
38  
39 noradrenergic tonic inhibition [20, 48]. Recent studies in humans have suggested that the  $\alpha_2$ -  
40  
41 AR may also play an important role in development of diabetes. A single-nucleotide  
42  
43 polymorphism in the human *ADRA2A* gene has been correlated with overexpression of  $\alpha_{2A}$ -  
44  
45 AR, reduced insulin secretion, and increased risk for type 2 diabetes [22]. Consistent with  
46  
47 these findings, a GWA study has recently linked the *ADRA2A* locus with beta-cell  
48  
49 dysfunction in humans with Type 2 diabetes [23].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 Basal lipolysis was significantly increased in male *Irs-2<sup>-/-</sup>* adipocytes whereas it was  
2 markedly reduced in female *Irs-2<sup>-/-</sup>* in comparison to their WT controls. When we tested the  
3 anti-lipolytic effect of insulin on isolated fat cells, glycerol release was suppressed in WT  
4 samples but insulin had no significant inhibitory effect on lipolysis in adipocytes of male or  
5 female *Irs-2<sup>-/-</sup>* mice. This results suggest that IRS2 may play a role in regulating insulin  
6 sensitivity in adipose tissue. Thus, our lipolysis data confirm the presence of insulin resistance  
7 and hyperinsulinemia in male *Irs-2<sup>-/-</sup>* mice. In female *Irs-2<sup>-/-</sup>* animals, not only was the basal  
8 rate of lipolysis reduced in comparison to WT females but the expected lipolytic response to  
9 either isoproterenol or forskolin was clearly attenuated; even at a concentration of  $10^{-6}$  M, the  
10 glycerol release evoked by isoproterenol was reduced by approximately 50% in adipocytes of  
11 *Irs-2<sup>-/-</sup>* females. Consistent with this altered lipolytic response, cAMP generation in response  
12 to isoprenaline and forskolin was reduced in adipocytes of *Irs-2<sup>-/-</sup>* females as compared with  
13 female controls, suggesting that post-receptor defects may contribute to the catecholamine  
14 resistance in these animals. The enhanced lipolytic response to forskolin in adipocytes of male  
15 *Irs-2<sup>-/-</sup>* adipocytes was associated with increased production of cAMP. Given that we detected  
16 reduced expression of  $\alpha_{2A}$ -AR in islets of male *Irs-2<sup>-/-</sup>*, it is possible that the absence of an  $\alpha_2$   
17 AR inhibitory effect also increases cAMP levels in male *Irs-2<sup>-/-</sup>* adipocytes, thereby  
18 predisposing them to an increased basal rate of lipolysis.

19 The observation that PKA-mediated phosphorylation of perilipin is significantly  
20 reduced in adipose tissue is consistent with the defective accumulation of cAMP in fat cells of  
21 female *Irs-2<sup>-/-</sup>* mice. Moreover, female *Irs-2<sup>-/-</sup>* adipocytes display another defect not present in  
22 their male counterparts which is a significant reduction in the expression of HSL. In *Irs1<sup>-/-</sup>*  
23 mice, which are lean and resistant to the effects of high-fat diet, HSL expression in adipocytes  
24 is enhanced more than 4-fold [49,50], suggesting that IRS1 and IRS2 may differentially  
25 regulate expression of lipolytic enzymes. These data provide a molecular explanation for the

1 development of moderate obesity in female *Irs2*-deficient animals; since phosphorylation of  
2 perilipin by PKA is required for the translocation of HSL to lipid droplets, the observed  
3 defects in adipocytes of female *Irs-2<sup>-/-</sup>* would be expected to impair lipolysis and facilitate fat  
4 storage. Interestingly, diminished expression of HSL has been observed in patients with  
5 obesity and Type 2 diabetes [51, 52]. Studies in humans have also demonstrated that the  
6 expression of  $\beta$ -AR2 and the regulatory II $\beta$ -subunit of PKA are reduced in adipocytes of  
7 female patients with polycystic ovary disease (PCOS), a common endocrine disorder  
8 characterized by obesity and insulin resistance [53, 54]. These defects are associated with  
9 catecholamine resistance and decreased lipolytic activity *in vivo* which promotes obesity in  
10 PCOS patients. In addition to the metabolic abnormalities characterized by beta cell failure  
11 and insulin resistance, *Irs-2<sup>-/-</sup>* females are infertile as IRS-2 signals are required for ovarian  
12 function and proper regulation of the reproductive axis [36, 55]. Thus, the presence of  
13 catecholamine resistance and perturbed cAMP signaling in adipose tissue of *Irs-2<sup>-/-</sup>* females  
14 suggest that these mice may represent a valid model for unravelling the molecular  
15 mechanisms underlying the pathology of PCOS.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 In summary, the sexual dimorphism described for the diabetic phenotype of *Irs-2<sup>-/-</sup>*  
37 mice can be explained, at least partially, by differential defects in pancreatic islets and adipose  
38 tissue. In female *Irs-2<sup>-/-</sup>* mice at 8-10 weeks of age, reduced basal lipolysis and catecholamine  
39 resistance in adipocytes are paired with a normal secretory response to glucose in pancreatic  
40 beta cells. Conversely, in male *IRS2*-deficient mice of the same age, basal lipolysis is  
41 enhanced as adipocytes are resistant to both insulin and to the inhibitory effects of  $\alpha_2$  AR  
42 agonists, a situation that requires increased secretion of insulin and favours a more rapid  
43 progression of diabetes. These metabolic differences between male and female *Irs-2<sup>-/-</sup>* mice  
44 must also reflect some influence of sex steroid hormones. In addition to its role in the  
45 physiology of reproduction, estrogen modulates metabolic parameters. For example, estrogen  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 plays an essential role in adaption to pregnancy by enhancing insulin biosynthesis and  
2 glucose-stimulated insulin secretion [56]. However, as both gonadotropins and steroid  
3 hormones are reduced in the infertile *Irs2<sup>-/-</sup>* females [36, 55], it is unlikely that the influence of  
4 estrogen and progesterone on gene expression has a major role in delaying the progression of  
5 diabetes in females versus males of this experimental model. The metabolic alterations which  
6 underlie this sexual dimorphism appear to be associated with differential defects in the cAMP  
7 system, including reduced expression of  $\alpha_2$  AR in  $\beta$ -cells of male *Irs-2<sup>-/-</sup>* and impaired  
8 generation of cAMP in adipose tissue of female *Irs-2<sup>-/-</sup>* mice.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

22 **ACKNOWLEDGEMENTS:** This work was supported by Instituto de Salud Carlos III-FIS  
23 grant PI03/0652, Fundación Mutua Madrileña, CIBER de Diabetes y Enfermedades  
24 Metabólicas del Instituto de Salud ISCIII, EMER007 (ISCIII), Ministerio de Ciencia y  
25 Innovación SAF2008-00011, Programa de Juan de la Cierva del MICINN (Silvia Sanz), and  
26 the Regenerative Medicine Program of the Valencian Community.  
27  
28  
29  
30  
31  
32  
33  
34  
35

## 36 REFERENCES

- 37  
38  
39 [1] Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse  
40 models. *J Clin Invest* 2000;106:459-465.  
41 [2] Oriol RC, Wiley CD, Dewey MJ, Vrana PB. Adaptive genetic variation, stress and  
42 glucose regulation. *Dis Model Mech* 2008;1:255-263.  
43 [3] Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al. Disruption of  
44 *IRS-2* causes type 2 diabetes in mice. *Nature* 1998;391:900-904.  
45 [4] Wells JC. Sexual dimorphism of body composition. *Best Pract Res Clin Endocrinol*  
46 *Metab* 2007;21:415-430.  
47 [5] Amrani A, Durant S, Throsby M, Coulaud J, Dardenne M, Homo-Delarche F. Glucose  
48 homeostasis in the nonobese diabetic mouse at the prediabetic stage. *Endocrinology*  
49 1998;139:1115-1124.  
50 [6] Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related  
51 strains. *Adv Immunol* 1992;51:285-322.  
52 [7] Ahren B. Evidence that autonomic mechanisms contribute to the adaptive increase in  
53 insulin secretion during dexamethasone-induced insulin resistance in humans.  
54 *Diabetologia* 2008;51:1018-1024.  
55 [8] Ahren B. Autonomic regulation of islet hormone secretion--implications for health  
56 and disease. *Diabetologia* 2000;43:393-410.  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1 [9] Redmon JB, Towle HC, Robertson RP. Regulation of human insulin gene  
2 transcription by glucose, epinephrine, and somatostatin. *Diabetes* 1994;43:546-551.
- 3 [10] Robertson RP, Halter JB, Porte D, Jr. A role for alpha-adrenergic receptors in  
4 abnormal insulin secretion in diabetes mellitus. *J Clin Invest* 1976;57:791-795.
- 5 [11] Christensen NJ. Catecholamines and diabetes mellitus. *Diabetologia* 1979;16:211-224.
- 6 [12] Isles CG, Johnson JK. Pheochromocytoma and diabetes mellitus: further evidence  
7 that alpha 2 receptors inhibit insulin release in man. *Clin Endocrinol (Oxf)*  
8 1983;18:37-41.
- 9 [13] Stenstrom G, Sjostrom L, Smith U. Diabetes mellitus in pheochromocytoma. Fasting  
10 blood glucose levels before and after surgery in 60 patients with pheochromocytoma.  
11 *Acta Endocrinol (Copenh)* 1984;106:511-515.
- 12 [14] Ostenson CG, Cattaneo AG, Doxey JC, Efendic S. Alpha-adrenoceptors and insulin  
13 release from pancreatic islets of normal and diabetic rats. *Am J Physiol*  
14 1989;257:E439-443.
- 15 [15] Guillot E, Coste A, Angel I. Alpha 2-adrenoceptors and the regulation of glucose,  
16 insulin and amylin levels in diabetic rats. *Life Sci* 1995;57:2081-2090.
- 17 [16] Nakaki T, Nakadate T, Ishii K, Kato R. Postsynaptic alpha-2 adrenergic receptors in  
18 isolated rat islets of Langerhans: inhibition of insulin release and cyclic 3':5'-adenosine  
19 monophosphate accumulation. *J Pharmacol Exp Ther* 1981;216:607-612.
- 20 [17] Drews G, Debuyser A, Nenquin M, Henquin JC. Galanin and epinephrine act on  
21 distinct receptors to inhibit insulin release by the same mechanisms including an  
22 increase in K<sup>+</sup> permeability of the B-cell membrane. *Endocrinology* 1990;126:1646-  
23 1653.
- 24 [18] Rorsman P, Bokvist K, Ammala C, Arkhammar P, Berggren PO, Larsson O, et al.  
25 Activation by adrenaline of a low-conductance G protein-dependent K<sup>+</sup> channel in  
26 mouse pancreatic B cells. *Nature* 1991;349:77-79.
- 27 [19] Nilsson T, Arkhammar P, Rorsman P, Berggren PO. Inhibition of glucose-stimulated  
28 insulin release by alpha 2-adrenoceptor activation is paralleled by both a  
29 repolarization and a reduction cytoplasmic free Ca<sup>2+</sup> concentration. *J Biol Chem*  
30 1988;263:1855-1860.
- 31 [20] Savontaus E, Fagerholm V, Rahkonen O, Scheinin M. Reduced blood glucose levels,  
32 increased insulin levels and improved glucose tolerance in alpha2A-adrenoceptor  
33 knockout mice. *Eur J Pharmacol* 2008;578:359-364.
- 34 [21] Devedjian JC, Pujol A, Cayla C, George M, Casellas A, Paris H, Bosch F. Transgenic  
35 mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered  
36 regulation of glucose homeostasis. *Diabetologia* 2000;43:899-906.
- 37 [22] Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ, et al.  
38 Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes.  
39 *Science* 2010;327:217-220.
- 40 [23] Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, Jackson AU, et al. New  
41 genetic loci implicated in fasting glucose homeostasis and their impact on type 2  
42 diabetes risk. *Nat Genet* 2010;42:105-116.
- 43 [24] Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological  
44 strategies against obesity and the metabolic syndrome. *Pharmacol Res* 2006;53:482-  
45 491.
- 46 [25] Alexander SP, Mathie A, Peters JA. *Guide to Receptors and Channels (GRAC)*, 3rd  
47 edition. *Br J Pharmacol* 2008;153:S1-209.
- 48 [26] Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y. The effects of  
49 beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAY mice. *Eur J Pharmacol* 2008;584:202-206.
- [27] Fain JN, Garcija-Sainz JA. Adrenergic regulation of adipocyte metabolism. *J Lipid Res* 1983;24:945-966.
- [28] Butler AA, Cone RD. Knockout models resulting in the development of obesity. *Trends Genet* 2001;17:S50-54.
- [29] Arner P. Human fat cell lipolysis: biochemistry, regulation and clinical role. *Best Pract Res Clin Endocrinol Metab* 2005;19:471-482.
- [30] Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, Strosberg AD. Molecular characterization of the human beta 3-adrenergic receptor. *Science* 1989;245:1118-1121.
- [31] Kitamura T, Kahn CR, Accili D. Insulin receptor knockout mice. *Annu Rev Physiol* 2003;65:313-332.
- [32] Burks DJ, White MF. IRS proteins and beta-cell function. *Diabetes* 2001;50:S140-145.
- [33] Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. *Diabetes* 2000;49:1880-1889.
- [34] Hashimoto H, Arai T, Ohnishi Y, Eto T, Ito M, Hioki K, et al. Phenotypes of IRS-2 deficient mice produced by reproductive technology are stable. *Exp Anim* 2007;56:149-154.
- [35] Tobe K, Suzuki R, Aoyama M, Yamauchi T, Kamon J, Kubota N, et al. Increased expression of the sterol regulatory element-binding protein-1 gene in insulin receptor substrate-2(-/-) mouse liver. *J Biol Chem* 2001;276:38337-38340.
- [36] Burks DJ, Font de Mora J, Schubert M, Withers DJ, Myers MG, Towery HH, et al. IRS-2 pathways integrate female reproduction and energy homeostasis. *Nature* 2000;407:377-382.
- [37] Iglesias-Osma MC, Garcia-Barrado MJ, Visentin V, Pastor-Mansilla MF, Bour S, Prevot D, Valet P, Moratinos J, Carpenne C. Benzylamine exhibits insulin-like effects on glucose disposal, glucose transport, and fat cell lipolysis in rabbits and diabetic mice. *J Pharmacol Exp Ther* 2004;309:1020-1028.
- [38] Garcia-Barrado MJ, Ravier MA, Rolland JF, Gilon P, Nenquin M, Henquin JC. Inhibition of protein synthesis sequentially impairs distinct steps of stimulus-secretion coupling in pancreatic beta cells. *Endocrinology* 2001;142:299-307.
- [39] Detimary P, Jonas JC, Henquin JC. Possible links between glucose-induced changes in the energy state of pancreatic B cells and insulin release. Unmasking by decreasing a stable pool of adenine nucleotides in mouse islets. *J Clin Invest* 1995;96:1738-1745.
- [40] Kubota N, Terauchi Y, Tobe K, Yano W, Suzuki R, Ueki K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. *J Clin Invest* 2004;114:917-927.
- [41] Valverde AM, Burks DJ, Fabregat I, Fisher TL, Carretero J, White MF, Benito M. Molecular mechanisms of insulin resistance in IRS-2-deficient hepatocytes. *Diabetes* 2003;52:2239-2248.
- [42] Ducharme NA, Bickel PE. Lipid droplets in lipogenesis and lipolysis. *Endocrinology* 2008;149:942-949.
- [43] Granneman JG. Delivery of DNA into adipocytes within adipose tissue. *Methods Mol Biol* 2008;423:191-195.
- [44] Shen WJ, Patel S, Miyoshi H, Greenberg AS, Kraemer FB. Functional interaction of hormone-sensitive lipase and perilipin in lipolysis. *J Lipid Res* 2009.

- 1 [45] Grill V, Cerasi E. Activation by glucose of adenylyl cyclase in pancreatic islets of the  
2 rat. FEBS Lett 1973;33:311-314.
- 3 [46] Delmeire D, Flamez D, Hinke SA, Cali JJ, Pipeleers D, Schuit F. Type VIII adenylyl  
4 cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.  
5 Diabetologia 2003;46:1383-1393.
- 6 [47] Tengholm A, Gylfe E. Oscillatory control of insulin secretion. Mol Cell Endocrinol  
7 2009;297:58-72.
- 8 [48] Ste Marie L, Palmiter RD. Norepinephrine and epinephrine-deficient mice are  
9 hyperinsulinemic and have lower blood glucose. Endocrinology 2003;144:4427-4432.
- 10 [49] Tsuji Y, Kaburagi Y, Terauchi Y, Satoh S, Kubota N, Tamemoto H, et al. Subcellular  
11 localization of insulin receptor substrate family proteins associated with  
12 phosphatidylinositol 3-kinase activity and alterations in lipolysis in primary mouse  
13 adipocytes from IRS-1 null mice. Diabetes 2001;50:1455-1463.
- 14 [50] Selman C, Lingard S, Choudhury AI, Batterham RL, Claret M, Clements M, et al.  
15 Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor  
16 substrate 1 null mice. FASEB J 2008;22:807-818.
- 17 [51] Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation  
18 in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998;24:409-418.
- 19 [52] Watt MJ, Carey AL, Wolsk-Petersen E, Kraemer FB, Pedersen BK, Febbraio MA.  
20 Hormone-sensitive lipase is reduced in the adipose tissue of patients with type 2  
21 diabetes mellitus: influence of IL-6 infusion. Diabetologia 2005;48:105-112.
- 22 [53] Faulds G, Ryden M, Ek I, Wahrenberg H, Arner P. Mechanisms behind lipolytic  
23 catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome.  
24 J Clin Endocrinol Metab 2003;88:2269-2273.
- 25 [54] Ek I, Arner P, Bergqvist A, Carlstrom K, Wahrenberg H. Impaired adipocyte lipolysis  
26 in nonobese women with the polycystic ovary syndrome: a possible link to insulin  
27 resistance?. J Clin Endocrinol Metab 1997;82:1147-1153.
- 28 [55] Neganova I, Al-Qassab H, Heffron H, Selman C, Choudhury AI, Lingard SJ, et al.  
29 Role of central nervous system and ovarian insulin receptor substrate 2 signaling in  
30 female reproductive function in the mouse. Biol Reprod 2007;76:1045-1053.
- 31 [56] Nadal A, Alonso-Magdalena P, Soriano S, Ropero AB, Quesada I. The role of  
32 oestrogens in the adaptation of islets to insulin resistance. J Physiol 2009;587:5031-  
33 5037.
- 34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 FIGURE LEGENDS

### 45 **Figure 1. Characterization of beta cell function in male and female mice.**

46 (A) Fed blood glucose levels were measured in animals of 8-10 weeks of age. n= 14 male  
47

48 WT, 14 male *Irs-2<sup>-/-</sup>*, 16 females WT and 18 females *Irs-2<sup>-/-</sup>*. \*\*\* p< 0.001, \*\* p< 0.01. (B)  
49

50 Circulating insulin levels from fed animals were measured by ELISA. n= 14 male WT, 14  
51

52 male *Irs-2<sup>-/-</sup>*, 16 female WT and 18 female *Irs-2<sup>-/-</sup>*. \*\*p< 0.01 (C) Quantification of beta cell  
53

54 area. Animals were sacrificed at 8-10 weeks of age. Pancreas sections were stained with anti-  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 insulin antibodies and beta cell area was determined using serial sections. n= 4 male WT, 4  
2 male *Irs-2<sup>-/-</sup>*, 3 female WT and 4 female *Irs-2<sup>-/-</sup>*. \*\*p < 0.01. (D) Total insulin content was  
3 determined from isolated islets by radioimmunoassay and plotted as  $\mu$ units of total insulin  
4 content per islet. For the experiment, 25-30 batches of three islets from the experimental  
5 groups were matched carefully by size. Data represent the average  $\pm$  SEM of 6 WT and 6 *Irs-*  
6 *2<sup>-/-</sup>* animals. \*\*p < 0.01. (E) Glucose-stimulated insulin release was measured in the presence  
7 of 3, 15 and 30 mM of glucose in islets isolated from male or (F) female animals (8-10 weeks  
8 of age). Insulin levels were determined by radioimmunoassay and plotted as  $\mu$ units of insulin  
9 per islet/h. n=9 males of each genotype and n=10 females of each genotype. \*\*\* p < 0.001, \*\*  
10 p < 0.01. Note: The results of the female *Irs-2<sup>-/-</sup>* were identical to female WT control and thus,  
11 the lines of the graph in F are superimposed.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 **Figure 2. Analysis of insulin release in male and female mice.** (A) The effects of carbachol  
30 (100  $\mu$ M) and brimonidine (UK14,304, 1 $\mu$ M) on insulin release were tested in islets of male  
31 and female mice (8-10 weeks of age). Pancreatic islets were incubated for 60 min in 1 ml of  
32 bicarbonate-buffered medium (HCOS medium supplemented with 1 mg/ml of BSA and 5 mM  
33 HEPES, see Methods) containing the indicated drug concentrations and 15 mM glucose.  
34 Values are expressed as percentages of mean control (100%, 15mM glucose of each animal)  $\pm$   
35 SEM of 10-15 batches of three islets from 8-10 animals. \**p*<0.05. (B) Expression of the  $\alpha$ -2A-  
36 AR in isolated islets of male mice was analysed by Western blotting. Anti-beta tubulin was  
37 used to confirm equal loading of samples. Islets were pooled from three animals of each  
38 genotype. (C) The effects of forskolin (FK, 1 $\mu$ M) on insulin release were tested in isolated  
39 islets as indicated in A. Values are expressed as percentages of mean control (100%, glucose  
40 15mM)  $\pm$  SEM of 10-15 batches of three islets from 8-10 animals. \*\*\**p*<0.05. (D) Islets were  
41 isolated as described and incubated in HCOS medium (see Methods) containing 3 mM  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 glucose. Subsequently, batches of 100 size-matched islets from each genotype were selected.  
2 Islets were then stimulated with either forskolin or 15 mM glucose for 10 minutes as  
3 described in C. The stimulation with forskolin was performed in triplicate and samples were  
4  
5 lysed to measure intracellular cAMP.  $**p < 0.01$ ,  $*p < 0.05$ .  
6  
7  
8  
9

10  
11 **Figure 3. Basal glycerol release in isolated adipocytes and inhibition by insulin. (A)**  
12 Following isolation of adipocytes from abdominal fat, basal lipolytic activity in wild-type vs.  
13  $Irs2^{-/-}$  mice (8-10 weeks of age) was measured. Values are expressed as means  $\pm$  SE obtained  
14 from the analysis of the following groups of mice: male WT (n = 29), male  $Irs2^{-/-}$  (n = 28),  
15 female WT (n = 46) and female  $Irs2^{-/-}$  (n = 41). Data are expressed relative to basal lipolysis,  
16 which was set as 100% in WT animals of each gender (absolute values for basal glycerol  
17 released in WT mice were  $0.34 \pm 0.05$  and  $0.42 \pm 0.02$   $\mu\text{mol}/100$  mg lipid/90 min for male  
18 and female, respectively).  $**p < 0.01$  and  $*p < 0.05$ . (B and C) Anti-lipolytic effect of insulin  
19 on basal glycerol release. Increasing concentrations of insulin ( $10^{-8}$  and  $10^{-7}$  M) were added to  
20 the incubation media and the percentage of inhibition of glycerol release from adipocytes of  
21 male (B) and female (C) mice was measured.  $**p < 0.01$  and  $*p < 0.05$ .  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 **Figure 4. Analysis of adrenergic-regulated lipolysis in adipocytes.**

42 (A and B) Analysis of isoproterenol-induced glycerol release. Fat cells from WT and  $Irs2^{-/-}$   
43 male (A) and female (B) mice of 8-10 weeks of age were incubated 90 min with increasing  
44 concentrations ( $10^{-9}$  –  $10^{-6}$  M) of the  $\beta$ -adrenergic agonist, isoproterenol (Iso). Basal lipolysis  
45 was considered as 100% in WT animals of each gender. Data are presented as means  $\pm$  SE  
46 (see Fig. 3A for absolute values in WT mice).  $*p < 0.05$  and  $**p < 0.01$ . n= 6 mice of each  
47 experimental group. (C and D) Effects of the  $\alpha 2$ -adrenergic agonist brimonidine (UK 14,304)  
48 on isoproterenol-induced glycerol release from mouse adipocytes. Values are expressed as  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

mean  $\pm$  SE relative to the percentage of WT basal values (100% of WT of each gender). \* $p$  <0.05 and \*\* $p$  <0.01.  $n$ = 4 mice of each experimental group.


**Figure 5. cAMP-mediated glycerol liberation in isolated mouse adipocytes.**


(**A and B**) Effects of 10  $\mu$ M forskolin (FK) on basal lipolysis. Basal lipolysis was established as 100% in WT animals of each gender. \*\*\* $p$  <0.001.  $n$ = 4 animals of each experimental group. (**C**) Triplicates of isolated adipocytes from each experimental group were stimulated with the indicated concentrations of either isoproterenol or forskolin for 10 min. Samples were then lysed and assayed for intracellular cAMP.  $n$ = 6 mice of each experimental group. \* $P$  <0.05 and \*\* $P$  <0.01.




**Figure 6. Analysis of cAMP-dependent signaling in adipose tissue.** (**A**) Western analysis of perilipin A/B expression and phosphorylation. Visceral adipose tissue was removed and protein lysates were prepared from four animals of each genotype. 500  $\mu$ g of total protein were immunoprecipitated (from pools of two animals of each experimental group) using anti-perilipin A/B and these immunocomplexes were then separated by SDS-PAGE. The membrane was first incubated with anti-phospho PKA substrate to detect phosphorylated perilipin A/B. Subsequently, the blot was stripped and re-probed to reveal total levels of perilipin A/B. Blots were scanned and phospho-perilipin A (approximately 62 kDa) was quantified by densitometry. Total perilipin A/B was used to normalize the levels of phospho-perilipin A/B. A representative blot from two independent experiments is presented. Total  $n$  = 8 animals of each group. (**B**) Western analysis of hormone-sensitive lipase expression in adipose tissue. 50  $\mu$ g of the adipose tissue lysates prepared in **A** were probed with anti-HSL antibodies. Anti-beta actin was used to confirm equal protein loads. Molecular weight is indicated at the left of each membrane.


Accepted Manuscript


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

















# Gender Differences in IRS2 Model of Diabetes

